Fortrea Holdings Inc. (FTRE) 股票分析

公司概述

Fortrea Holdings Inc. operates globally as a contract research organization, delivering specialized solutions for the development of biopharmaceutical products and medical devices to pharmaceutical, biotechnology, and medical device clients. The company functions within the Healthcare sector and specifically the Biotechnology industry, focusing on areas such as clinical pharmacology, clinical research units, external partnerships, and project-based services. As of the latest data, the company holds a market capitalization of $877.03M and reports an annual revenue of $2.72B, employing a workforce of 13,871 individuals. These financial figures indicate that Fortrea maintains a substantial operational scale within the biotech services landscape, positioning it as a significant player capable of supporting large-scale drug and device development pipelines for its diverse client base.

财务健康

Fortrea Holdings Inc. reported a revenue of $2.72B over the trailing twelve months, yet it recorded a net income of -$986,200,000, while generating an EBITDA of $41.50M. The substantial gap between the $2.72B revenue and the negative net income of approximately $986 million reveals a highly expansive cost structure where operational expenses significantly outpace gross profits, resulting in a net loss despite positive earnings before interest, taxes, depreciation, and amortization. The company generated positive free cash flow of $196.05M, which suggests a degree of financial flexibility in converting operations into cash, although this must be weighed against the company's total debt of $1.12B. Analyzing the three key margins, the company shows a gross margin of 18.5%, an operating margin of 1.3%, and a profit margin of -36.2%; these figures indicate that while the company retains value after cost of goods sold, its operating leverage is under pressure, and the negative profit margin reflects the high overhead typical of early-stage or heavy-research biotech services. In terms of balance sheet leverage, total cash stands at $174.60M against total debt of $1.12B, resulting in a debt-to-equity ratio of 198.26, which characterizes the balance sheet as highly leveraged. The current ratio is 0.98, indicating that the company's current assets fall slightly short of covering its current liabilities, suggesting tight short-term liquidity conditions. Furthermore, the return on equity is -102.4% and the return on assets is -0.6%, metrics that reveal that management has not yet achieved profitability on shareholder investments or total assets, highlighting the challenges in generating returns from the substantial capital deployed in research and development activities.

估值评估

The valuation metrics for Fortrea Holdings Inc. show a trailing P/E ratio of N/A and a forward P/E of 9.91, implying that the market is pricing the stock based on anticipated future earnings recovery rather than historical performance. The price-to-book ratio stands at 1.55, indicating that the market values the company at a moderate premium over its tangible book value, potentially reflecting the value of its intangible assets and future growth prospects. Alternative valuation measures include a price-to-sales ratio of 0.32 and an EV/EBITDA of 43.85; the low price-to-sales suggests the stock is trading at a discount relative to its sales volume, while the high EV/EBITDA of 43.85 reflects the premium investors are willing to pay for future earnings potential despite current losses. Regarding price volatility, the stock has a 52-week high of $18.67 and a 52-week low of $3.97; without the exact current price, the specific trading position relative to this range cannot be calculated, but the wide range indicates significant price fluctuation over the past year. The beta value is 1.77, which means the stock's price volatility is significantly higher than the broader market, moving roughly 77% more than the market index during periods of fluctuation.

Growth & Income

Fortrea Holdings Inc. experienced a revenue growth of -5.2% year-over-year, while the earnings growth rate is N/A due to the company's net loss; the negative revenue growth combined with N/A earnings growth indicates that the company is currently shrinking its top line rather than growing faster than its costs. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available earnings back into its research operations and growth initiatives rather than distributing cash to shareholders. This strategy of zero dividends aligns with the biotechnology industry practice of retaining capital to fund expensive clinical trials and product development cycles. Overall, the company's growth and income profile is characterized by declining revenue, negative profitability, and a lack of dividend income, positioning it as a high-risk, high-potential growth stock that relies entirely on future clinical successes to restore earnings and revenue trajectories.